Pixium Vision SA
PAR:ALPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (2), the stock would be worth €-3.95 (1 150% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | €0.38 |
0%
|
| Industry Average | 2 | €-3.95 |
-1 150%
|
| Country Average | 6.7 | €-13.57 |
-3 705%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Pixium Vision SA
PAR:ALPIX
|
1.5m EUR | -0.2 | -0.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 52.9 | 56.1 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 16.6 | 25.3 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 23.8 | 37 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 13.9 | 22 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 18.5 | 23.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 29.6 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 36.9 | 41.1 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
38.3B EUR | 12.6 | 18.1 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 12.2 | 23.5 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 16.2 | 20.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.4 |
| Median | 6.7 |
| 70th Percentile | 12 |
| Max | 2 287.4 |
Other Multiples
Pixium Vision SA
Glance View
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
